FDA Should Reaffirm Drug Sponsor Right To Decide ADR Follow-Up - PhRMA
Executive Summary
FDA should "reaffirm in writing" that a drug sponsor "should and does have the right to determine the appropriate follow-up for adverse experience reports," the Pharmaceutical Research & Manufacturers of America maintained in comments submitted to FDA March 2.